Therefore, regulating the expression of PD-L1 on the tumor cells and alleviating the TIME to promote the infiltration of CTLs are critical to improve the response rate of PD-1/PD-L1 ICB therapy. The gene discussed is PDCD1; the disease is neoplasm.